A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Studyof Epratuzumab in Patients with Active Systemic Lupus Erythematosus

The primary study objective is to demonstrate that epratuzumab is effective for improvement of the signs and symptoms of SLE.